Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 21, 2006; 12(27): 4420-4424
Published online Jul 21, 2006. doi: 10.3748/wjg.v12.i27.4420
Published online Jul 21, 2006. doi: 10.3748/wjg.v12.i27.4420
Table 1 Epidemiological, virological and histological baseline data of group-1 and group-2 CHC patients of the study population
| Group 1(n = 15) | Group 2(n = 15) | P-value | |
| Age (yr) | 26.9 ± 3.8 | 27.3 ± 4.1 | 0.510 |
| Sex (male/female) | 8/7 | 9/6 | 0.713 |
| ΒΜΙ (kgr/m2) | 22.45 ± 1.8 | 22.12 ± 0.9 | 0.390 |
| HCV-RNA (-log10 IU/mL) | 5.32 ± 0.67 | 5.24 ± 0.52 | 0.765 |
| Grade (0-18) | 5.6 ± 2.3 | 4.2 ± 1.5 | 0.089 |
| Stage (0-6) | 1.3 ± 0.5 | 1.5 ± 0.7 | 0.276 |
| Genotype (1/non-1) | 3/12 | 2/13 | 0.624 |
- Citation: Elefsiniotis IS, Vezali E, Kamposioras K, Pantazis KD, Tontorova R, Ketikoglou I, Moulakakis A, Saroglou G. Immunogenicity of recombinant hepatitis B vaccine in treatment-naïve and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment. World J Gastroenterol 2006; 12(27): 4420-4424
- URL: https://www.wjgnet.com/1007-9327/full/v12/i27/4420.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i27.4420